
You must be at least 21 years old to access this website.
Our Products are for research and/or investigative purposes and are not suitable for direct human consumption or consumers, nor are they intended for clinical or therapeutic use. The statements and products listed on this website are not intended to diagnose, treat, cure, or prevent any disease. As such, they have not been evaluated or approved by the Federal Food and Drug Administration (the “FDA”). We are not a compounding pharmacy or outsourcing facility as defined under either Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Your cart is empty
Add compounds to get started
Research Comparison
CJC-1295 is a GHRH analog that acts on the GHRH receptor, while Ipamorelin is a selective GH secretagogue acting on GHSR-1a. They target different receptors in the same growth-hormone axis, which is why researchers frequently study them together rather than as substitutes.
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Receptor target | GHRH receptor | GH secretagogue receptor (GHSR-1a) |
| Class | GHRH analog | GH secretagogue (GHRP) |
| Signaling profile | Sustained, long-acting (DAC) | Pulsatile, short-acting |
| Off-target release | Low | Very low (cortisol/prolactin sparing) |
| Common pairing | Paired with a GHRP | Paired with a GHRH analog |
Yes — because they act on different receptors in the growth-hormone axis, they are commonly combined in research to study synergistic GH pulse amplitude and frequency. We also offer a pre-made CJC-1295 + Ipamorelin blend.
CJC-1295 is a GHRH analog providing sustained receptor activation, while Ipamorelin is a selective secretagogue producing a clean, pulsatile signal. They are complementary rather than interchangeable.